How Direct‑to‑Consumer Drug Models Could Impact Employers

The pharmaceutical industry is entering a major transformation driven by two federal pricing reforms: the Inflation Reduction Act (IRA) and new Most Favored Nation (MFN) pricing initiatives signed in 2025. These changes will allow Medicare to negotiate lower prices on many high‑cost medications and tie U.S. drug prices more closely to those in other developed countries. As manufacturers face reduced margins and increasing pressure for price transparency, many are turning to a new strategy: selling medications directly to consumers at cash prices. While this trend is largely aimed at patients, it’s poised to have ripple effects on employer-sponsored health plans.

Direct‑to‑consumer (DTC) drug programs allow pharmaceutical companies to bypass traditional channels – like pharmacy benefit managers (PBMs) and retail pharmacies – and deliver medications straight to patients through their own digital platforms. Early movers are offering bundled services including telehealth visits, disease education tools, pharmacy fulfillment, and discounted cash‑pay options. These programs are gaining traction in high‑demand therapeutic areas for managing conditions like obesity, diabetes, migraines, and mental health, where patients have shown a willingness to pay out of pocket for faster, easier access to care. We have already seen manufacturers like Eli Lily and Pfizer make announcements for their own solutions.

So, why does this matter for you as an employer? We think this shift will have meaningful implications, both positive and negative. To start with the pros, DTC models could relieve pressure on group health plans in two ways. First, this gives employees alternative pathways to affordable medications – especially for those with high deductibles or limited coverage. These platforms often provide convenience, price transparency, and faster access to care, all of which may improve adherence and employee satisfaction. Second, for those in the large group or self-funded space, this means these drugs are not being routed through your plan, which reduces your overall claims. Conversely, this brings about possible complications as the growing availability of cash‑pay options could create complexities in care coordination, disrupt existing pharmacy networks, or challenge traditional plan design strategies aimed at managing high‑cost drugs.

As federal policy continues to reshape drug pricing, DTC programs are likely to expand and evolve. Employers and HR leaders should keep a close eye on this trend, as it may influence future benefit designs, employee expectations, pharmacy cost management strategies, and future compliance considerations. While still emerging, DTC models represent a potential shift toward more consumer‑centric healthcare and a development that could play an increasingly important role in how employees’ access and pay for essential medications.

Back to Overview